News about Manufacturing

Lupin's Aurangabad Facility Receives EIR from U.S. FDA

 Lupin's Aurangabad Facility Receives EIR from U.S. FDA

Pharma major Lupin Limited (Lupin) today announced the receipt of the Establishment Inspection Report (EIR) from the U.S. FDA for its Aurangabad, India facility. The inspection for the facility was carried out by the U.S. FDA between February 10, 2020 and February 14, 2020 and concluded with no observations

Manufacturing | 03/04/2020 | By Darshana

COVID-19 Testing Kits: Mylab Signs Deal With Serum

Mylab Discovery Solutions, the first Indian company whose testing kit was approved by the Indian Council of Medical Research (ICMR), has tied up with Serum Institute of India, world?s largest vaccine manufacturer by number of doses produced, to scale up the operations and escalate faster delivery of testing kits

Manufacturing | 02/04/2020 | By Darshana

Lupin launches Betamethasone Dipropionate Ointment USP (Augmented)

 Lupin launches Betamethasone Dipropionate Ointment USP (Augmented)

Pharma major Lupin Limited (Lupin) announced the launch of Betamethasone Dipropionate Ointment USP (Augmented), 0.05%, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier. The product would be manufactured at Lupin’s Pithampur (Unit III) facility, India

Manufacturing | 21/03/2020 | By Darshana

BELLUS Health Announces Completion of Enrollment in Phase 2 RELIEF Trial of BLU-5937 for the Treatment of Refractory Chronic Cough

 BELLUS Health Announces Completion of Enrollment in Phase 2 RELIEF Trial of BLU-5937 for the Treatment of Refractory Chronic Cough

BELLUS Health Inc, a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that it has completed patient enrollment for the RELIEF trial, its dose-escalation, placebo-controlled Phase 2 trial of BLU-5937 in patients

Manufacturing | 21/03/2020 | By Darshana

Medivir and Tango Therapeutics sign license agreement for preclinical asset

 Medivir and Tango Therapeutics sign license agreement for preclinical asset

Medivir today announced that it has entered into a license agreement with US biotech company Tango Therapeutics for one of Medivir’s preclinical research programs

Manufacturing | 17/03/2020 | By Darshana

Lupin launches Ethacrynic Acid Tablets USP

 Lupin launches Ethacrynic Acid Tablets USP

Pharma major Lupin Limited (Lupin) announced the launch of Ethacrynic Acid Tablets USP, 25 mg, having received approval from the United States Food and Drug Administration (U.S. FDA) earlier. The product would be manufactured at Lupin's Nagpur OSD facility, India

Manufacturing | 14/03/2020 | By Darshana


We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology
Subscribe to our newsletter